Abstract: BACKGROUND AND AIM OF THE STUDY: Non-alcoholic fatty liver disease (NAFLD) prevalence is on the rise across the world. NAFLD is found to be an independent risk factor for CVD after doing the adjustment for other common risk factors. Gamma-glutamyltransferase (GGT) is found to be a potential serum marker that has promising results for the prediction of CVD in the general population. The Framingham risk score (FRS), first developed depending on the data obtained from the Framingham Heart Study, is found to be a genderspecific algorithm used to determine the 10-year cardiovascular risk of an individual. This study was aimed to determine the role of γ- glutamyltransferase levels in prediction of high cardiovascular risk among patients with non-alcoholic fatty liver disease. MATERIALS AND METHODS: This study is a cross sectional study done among 50 patients attending the General Medicine and Medical Gastroenterology Department. This study is done in Govt. Madurai Medical College, in the year 2022. After the informed consent from participants, the study is conducted. The Data is then entered in MS Excel and analysed using SPSS. Appropriate descriptive statistics like Mean, SD and Percentage and inferential statistics like Fischer exact test is used. RESULTS: Our study shows that the Mean (SD) age is 48 years (11 years). About 38% are females and 62% are males. About 46% are smokers and 54% are non-smokers. The Mean (SD) SBP is 126 (12). The Mean (SD) T Cholesterol is 175 (33). The Mean (SD) HDL is 44 (7). The Mean (SD) LDL is 150 (23). The Mean (SD) SGOT is 45 (9). The Mean (SD) SGPT is 38 (8). The Mean (SD) GGT is 61 (18). About 38% are grade 3, 32% are grade 2 and 30% are grade 1. About 48% are high risk, 20% are moderate risk and 32% are low risk. About 70% are having GGT value of > 45 and 30% are having ≤45. Those with high and moderate Framingham risk have GGT of more than 45. Those with grade 3 fatty liver have GGT of more than 45. Those with grade 3 fatty liver have GGT are with high Framingham risk. There ...
No Comments.